search
Back to results

Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors (Privet)

Primary Purpose

Hypomagnesemia, Intestinal, With Secondary Hypocalcemia, Drug Induced Hypomagnesemia

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Inulin
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypomagnesemia, Intestinal, With Secondary Hypocalcemia focused on measuring hypomagnesemia, hypocalcemia, inulin, FOS, PPI, proton-pump inhibitors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Chronic PPI use
  • Hypomagnesemia

Exclusion Criteria:

  • Uncontrolled diabetes
  • Irregular use of the inulin fibers

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    No Intervention

    Arm Label

    Inulin

    No Inulin

    Arm Description

    Intervention by inulin, max 20gr per day

    Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)

    Outcomes

    Primary Outcome Measures

    Cases and controls: Mean serum Mg2+ treatment effect of inulin (composite measure)
    Measured values at respective timepoints are denoted as means +/- SEM in mmol/L. The treatment effect is calculated by the overall mean change of serum Mg2+ during the two inulin treated phases (Days 0 - 14 and days 28 - 42) and expressed as mean +/- SEM.

    Secondary Outcome Measures

    Cases and controls: Mean serum Ca2+ treatment effect of inulin (composite measure)
    Measured values at respective timepoints are denoted as means +/- SEM in mmol/L. The treatment effect is calculated by the overall mean change of serum Ca2+ during the two inulin treated phases (Days 0 - 14 and days 28 - 42) and expressed as mean +/- SEM.
    Cases only: 24-hrs urine Mg2+ excretion without inulin at days 27/28
    Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
    Cases only: 24-hrs urine Mg2+ excretion with inulin at days 41/42
    Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
    Cases only: 24-hrs urine Ca2+ excretion without inulin at days 27/28
    Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
    Cases only: 24-hrs urine Ca2+ excretion with Inulin at days 41/42
    Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
    Cases and controls: General demographics of PPI users (Composite measure)
    Demographical data, extracted from patient reports with relevant data such as age, sex, PPI-use and Duration and relevant comorbidities
    Cases and Controls: Genetic screen of polymorphisms in the TRPM6 gene
    Small PCR and Sanger sequencing of exons 26+27 of the gene TRPM6 (Mg2+ channel)

    Full Information

    First Posted
    June 26, 2015
    Last Updated
    August 5, 2015
    Sponsor
    Radboud University Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02518659
    Brief Title
    Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors
    Acronym
    Privet
    Official Title
    Inulin- a Potential Preventive Dietary Supplement Against PPI Induced Hypomagnesemia
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2014 (undefined)
    Primary Completion Date
    February 2015 (Actual)
    Study Completion Date
    June 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Radboud University Medical Center

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Hypomagnesemia is a severe side effect of longterm use of all available proton-pump inhibitors (PPIH). It develops due to intestinal malabsorption of Mg2+. This study investigates the application of dietary inulin fibers in users of proton-pump inhibitors with such a hypomagnesemia. To this end, repetitive short-term trials of 14 days of orally administered inulin, separated by a wash-out period of 14 days each were performed in cases of PPIH and controls. This study was not blinded or randomized.
    Detailed Description
    Hypomagnesemia due to PPI use (PPIH) has a low frequency, but is a difficult to control side effect in clinical practice. It develops over years and results in severe symptoms related to the hypomagnesemia. Due to the widespread use of PPIs, the real number of PPIH may be high. Currently, there is a lack of intervention strategies and no general treatment protocols for patients exist. It is generally anticipated that PPI-withdrawal and antacid replacement therapy is the only working method to recover patients from the hypomagnesemia. However, this frequently resulted in rebound of gastric acid related complaints. The molecular mechanism of PPIH involves a reduction of Mg2+ absorption by the large intestine. Inulin fibers have been shown to have prebiotic properties. The intestinal microbiome ferments inulin and releases butyrate into the luminal compartment of the intestine. This results in acidification which enhances the uptake of Mg2+ and Ca2+ mediated by pH-sensitive ionchannels.Thus inulin may counteract PPI induced reduction of luminal protons and therefore reestablish normal Mg2+ absorption. To this end cases with PPIH and controls underwent two 14 day trials of orally administered inulin under separated by wash-out periods of 14 days. During the experimental phase blood measures of electrolytes were monitored.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypomagnesemia, Intestinal, With Secondary Hypocalcemia, Drug Induced Hypomagnesemia
    Keywords
    hypomagnesemia, hypocalcemia, inulin, FOS, PPI, proton-pump inhibitors

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    21 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Inulin
    Arm Type
    Other
    Arm Description
    Intervention by inulin, max 20gr per day
    Arm Title
    No Inulin
    Arm Type
    No Intervention
    Arm Description
    Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Inulin
    Other Intervention Name(s)
    Beneo Orafti Synergy1
    Intervention Description
    This is the Intervention
    Primary Outcome Measure Information:
    Title
    Cases and controls: Mean serum Mg2+ treatment effect of inulin (composite measure)
    Description
    Measured values at respective timepoints are denoted as means +/- SEM in mmol/L. The treatment effect is calculated by the overall mean change of serum Mg2+ during the two inulin treated phases (Days 0 - 14 and days 28 - 42) and expressed as mean +/- SEM.
    Time Frame
    Cases and controls were followed for 56 days. Single measures of serum Mg2+ (in mmol/L) were performed at days 0, 14, 28,42 and 56.
    Secondary Outcome Measure Information:
    Title
    Cases and controls: Mean serum Ca2+ treatment effect of inulin (composite measure)
    Description
    Measured values at respective timepoints are denoted as means +/- SEM in mmol/L. The treatment effect is calculated by the overall mean change of serum Ca2+ during the two inulin treated phases (Days 0 - 14 and days 28 - 42) and expressed as mean +/- SEM.
    Time Frame
    Cases and controls were followed for 56 days. Single measures of serum Ca2+ (in mmol/L) were performed at days 0, 14, 28,42 and 56.
    Title
    Cases only: 24-hrs urine Mg2+ excretion without inulin at days 27/28
    Description
    Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
    Time Frame
    Collected 24-hrs urine samples are taken from each case at days 27/28. Samples were stored and measured within one week after day 56, the finalizing day of the respective participant.
    Title
    Cases only: 24-hrs urine Mg2+ excretion with inulin at days 41/42
    Description
    Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
    Time Frame
    Collected 24-hrs urine samples are taken from each case at days 41/42. Samples were stored and measured within one week after day 56, the finalizing day of the respective participant.
    Title
    Cases only: 24-hrs urine Ca2+ excretion without inulin at days 27/28
    Description
    Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
    Time Frame
    Collected 24-hrs urine samples are taken from each case at days 27/28. Samples were stored and measured within one week after day 56, the finalizing day of the respective participant.
    Title
    Cases only: 24-hrs urine Ca2+ excretion with Inulin at days 41/42
    Description
    Measured values for respective timepoint is denoted as a mean +/- SEM in mmol/24hrs.
    Time Frame
    Collected 24-hrs urine samples are taken from each case at days 41/42. Samples were stored and measured within one week after day 56, the finalizing day of the respective participant.
    Title
    Cases and controls: General demographics of PPI users (Composite measure)
    Description
    Demographical data, extracted from patient reports with relevant data such as age, sex, PPI-use and Duration and relevant comorbidities
    Time Frame
    at day 0
    Title
    Cases and Controls: Genetic screen of polymorphisms in the TRPM6 gene
    Description
    Small PCR and Sanger sequencing of exons 26+27 of the gene TRPM6 (Mg2+ channel)
    Time Frame
    DNA was extracted from blood, amplified and sequenced in average 2 months after bloodwithdrawal

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Chronic PPI use Hypomagnesemia Exclusion Criteria: Uncontrolled diabetes Irregular use of the inulin fibers
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    René Bindels, Professor
    Organizational Affiliation
    Radboud University Medical Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    22762246
    Citation
    Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012 Sep;36(5):405-13. doi: 10.1111/j.1365-2036.2012.05201.x. Epub 2012 Jul 4. Erratum In: Aliment Pharmacol Ther. 2012 Dec;36(11-12):1109.
    Results Reference
    background
    PubMed Identifier
    23756852
    Citation
    Lameris AL, Hess MW, van Kruijsbergen I, Hoenderop JG, Bindels RJ. Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6. Pflugers Arch. 2013 Nov;465(11):1613-20. doi: 10.1007/s00424-013-1306-0. Epub 2013 Jun 12.
    Results Reference
    background
    PubMed Identifier
    12514257
    Citation
    Coudray C, Demigne C, Rayssiguier Y. Effects of dietary fibers on magnesium absorption in animals and humans. J Nutr. 2003 Jan;133(1):1-4. doi: 10.1093/jn/133.1.1.
    Results Reference
    background

    Learn more about this trial

    Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors

    We'll reach out to this number within 24 hrs